(Q39254820)

English

Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Stephen R. Mattarollo

1

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

2

object named as

Kim Steegh

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

4

object named as

Helene Duret

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

author name string

Ming Li

3

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Shin Foong Ngiow

5

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

publication date

23 October 2012

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Immunology & Cell Biology

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

91

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

105-114

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Differential tumor surveillance by natural killer (NK) and NKT cells.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Secretion of IFN-gamma but not IL-17 by CD1d-restricted NKT cells enhances rejection of skin grafts expressing epithelial cell-derived antigen

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Differential antitumor immunity mediated by NKT cell subsets in vivo

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Raising the NKT cell family

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Targeting natural killer cells and natural killer T cells in cancer

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Glycolipid antigen induces long-term natural killer T cell anergy in mice

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

The impact of CD4+CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Control of NK cell functions by CD4+CD25+ regulatory T cells.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

IFN-gamma-producing human invariant NKT cells promote tumor-associated antigen-specific cytotoxic T cell responses.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

A protective function for interleukin 17A in T cell-mediated intestinal inflammation

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Alpha-galactosylceramide: potential immunomodulatory activity and future application

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Tumor-infiltrating T lymphocytes: friends or foes?

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

IL-17A directly inhibits TH1 cells and thereby suppresses development of intestinal inflammation

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

21 January 2018

Protection from type 1 diabetes by invariant NK T cells requires the activity of CD4+CD25+ regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

7 January 2021

based on heuristic

inferred from DOI database lookup

In vivo depletion of FoxP3+ Tregs using the DEREG mouse model

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

7 January 2021

based on heuristic

inferred from DOI database lookup

Cutting edge: depletion of Foxp3+ cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

7 January 2021

based on heuristic

inferred from DOI database lookup

Lipid length controls antigen entry into endosomal and nonendosomal pathways for CD1b presentation

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

7 January 2021

based on heuristic

inferred from DOI database lookup

Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

7 January 2021

based on heuristic

inferred from DOI database lookup

Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth

1 reference

https://api.crossref.org/works/10.1038%2FICB.2012.58

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/ICB.2012.58

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39254820&oldid=1816031090"